FindTrial
Sign In

Association Study of Hepatitis B Virus S Gene Mutations with the Risk of Hepatocellular Carcinoma Development

Association Study of Hepatitis B Virus S Gene Mutations with the Risk of Hepatocellular Carcinoma Development

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500097223
Enrollment
Unknown
Registered
2025-02-14
Start date
2025-03-01
Completion date
Unknown
Last updated
2025-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma (HCC) related to hepatitis B virus infection

Interventions

Observation group:None

Sponsors

Huzhou Center Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patient has not been treated with antiviral drugs in the last 1 year. The diagnostic criteria were referred to the Guidelines for the Prevention and Treatment of Chronic Hepatitis B, 2022 Edition and the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer, 2022 Edition, and serum samples were quantified by real-time PCR to quantify HBV-DNA, and samples with HBV-DNA >103 IU/ml were included in the study.

Exclusion criteria

Exclusion criteria: Excluding tuberculosis, HIV, HCV, and other hepatitis virus infections, as well as autoimmune liver diseases.

Design outcomes

Secondary

MeasureTime frame
Virology (genotype, viral load), immunology (hepatitis B trilineage), biochemistry (liver function-related enzymes) of serum samples sign;—

Countries

China

Contacts

Public ContactFuchu Qian

Huzhou Center Hospital

qfc313009@126.com+86 572 2555801

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026